Day: October 5, 2025

Innovative Non-Volatile Memory (NVM) technology to be available in 65nm BCD process HOD HASHARON, Israel, Oct. 05, 2025 (GLOBE NEWSWIRE) — Weebit Nano Limited (ASX:WBT) (Weebit), a leading developer and licensor of advanced memory technologies for the global semiconductor industry, has successfully taped-out (released to manufacturing) test chips featuring its embedded Resistive Random-Access Memory (ReRAM) module at onsemi’s 300mm production fab in East Fishkill, NY. The chips are being developed in onsemi’s Treo platform, which is a 65nm Bipolar-CMOS-DMOS (BCD) process. onsemi (Nasdaq: ON) is a U.S. based company that delivers intelligent power and sensing solutions for the automotive, industrial and AI data center markets. This tape-out represents a key milestone towards enabling Weebit ReRAM IP on onsemi’s Treo™ platform....

– ARV-102 was well tolerated in clinical trials for both healthy volunteers and patients with Parkinson’s disease – – ARV-102 demonstrated dose-dependent cerebrospinal fluid (CSF) exposure in subjects in both trials – – After 14 days of treatment in healthy volunteers, ARV-102 decreased lysosomal and neuroinflammatory microglial pathway biomarkers known to be elevated in Parkinson’s disease – NEW HAVEN, Conn., Oct. 05, 2025 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced positive pharmacokinetic, pharmacodynamic, and biomarker data from two Phase 1 clinical trials evaluating ARV-102, an oral, brain-penetrant investigational PROTAC degrader of leucine-rich repeat kinase 2 (LRRK2). Results were presented at...

Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data50 mg once-daily dose of obefazimod led to a pooled 16.4% (p

WALTHAM, Mass., Oct. 05, 2025 (GLOBE NEWSWIRE) — Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease (“IBD”) and other immune-mediated diseases, today announced scientific presentations at the UEGW Congress. “We are excited to share follow-up data out to six months from our Phase 1 study of SPY002, our potential best-in-class anti-TL1A agent in development for IBD. The data continue to show SPY002 is well tolerated, has a differentiated PK profile supporting quarterly or twice-yearly dosing, and suppresses free TL1A through 24 weeks,” said Josh Friedman, M.D., Ph.D., SVP of Clinical Development at Spyre. “Additionally, we are pleased to share new preclinical...

HONG KONG, Oct. 05, 2025 (GLOBE NEWSWIRE) — MOG Digitech Holdings Limited (01942.HK) announced the completion of a strategic investment in Luckyins Technology (HongKong) Co., Limited, an emerging force in Hong Kong’s insurtech sector. This move marks another significant step for MOG Digitech in driving the digital transformation of the insurance industry and advancing its ongoing strategic layout in Web3 insurance. Luckyins Technology (HongKong) Co., Limited is a tech enterprise focused on optimizing insurance business processes through AI technology, offering modular solutions that cover insurance sales, operations, finance, and after-sales management. Concurrently, the company also serves as a technical service provider utilizing blockchain technology to deliver digital payment solutions for the insurance industry. MOG...